The Veterans Bio-Medical Research Institute Inc.

The Veterans Bio-Medical Research Institute Inc., a tax-exempt nonprofit research organization based in East Orange, New Jersey, serves as a recipient of federal research grants from the Defense Health Agency and the National Institutes of Health, focusing on biomedical research addressing deployment-related and chronic health conditions in veterans and service members. The organization operates primarily as a prime grant recipient (82% of recent awards), with a smaller footprint as a sub-recipient under university-led grants from Rutgers, University of Delaware, and Baylor College of Medicine.

The Veterans Bio-Medical Research Institute holds eight prime grants from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), representing the majority of its federal footprint by both award count and focus. Recent Defense Health Agency prime grants include a $1.6 million project grant awarded November 1, 2026, investigating time-efficient, high-resistance inspiratory muscle training as a treatment for exertional dyspnea in deployed veterans (performance period through October 31, 2030), and a $1.1 million project grant awarded November 1, 2024, examining cardiovascular risk profiling of deployment-related respiratory diseases through translational research methods. An earlier Defense Health Agency grant from July 2022 supported research into reducing Gulf War-induced neurodegeneration through neuroinflammatory pathway modulation. The National Institutes of Health accounts for seven awards in the source data, anchoring the second-largest customer relationship. Beyond prime grants, the institute serves as a sub-recipient on federally funded research led by academic medical centers — including a January 2026 sub-award from Rutgers supporting medication prescribing evidence in older adults with chronic kidney disease, and two September 2024 sub-awards from the University of Delaware supporting optimization and feasibility testing of iManage-SCI, a system designed for veterans with spinal cord injury.

The organization's award portfolio reflects episodic federal research funding rather than continuous procurement. Between 2020 and 2026, the source captures three awards in 2020, one in 2021, one in 2022, four in 2024, and two in 2026. Combined potential value across all awards in the source totals $43 thousand, substantially eclipsed by combined dollars obligated of $19.7 million — indicating that the source's potential-value metric is incomplete or legacy-driven for this research-grant portfolio. The Defense Health Agency and National Institutes of Health together account for 86% of recent awards by count, with the Department of Defense and Army Medical Command forming a secondary customer set. Work is performed at the institute's facility in East Orange, New Jersey, with research collaborations extending to clinical trial execution, subject recruitment, and novel methodology development for linking military service, respiratory disease, and cardiovascular risk assessment.